Targeting the MHC II presentation pathway in allergy vaccine development

Area of Science:

• Immunology
• Vaccinology
• Molecular Biology

Background:

• Rising incidence of allergic diseases necessitates novel vaccination strategies.
• Current vaccines exhibit limited efficacy, highlighting the need for improved approaches.
• Protein transduction domain (PTD) technology offers a basis for enhanced antigen delivery.

Purpose of the Study:

• To engineer and evaluate modular antigen translocation (MAT) molecules for improved antigen presentation.
• To assess MAT vaccines' ability to target intracellular MHC II presentation pathways.
• To test the efficacy of MAT vaccines in stimulating immune responses and protecting against allergies.

Main Methods:

• Engineered MAT molecules by fusing Tat peptide to truncated invariant chain (Ii) for intracellular targeting.
• Compared recombinant allergens, Tat-conjugated allergens, and MAT-conjugated allergens in human PBMC cultures and mouse models.
• Assessed T-cell proliferation, cytokine production, and protection from anaphylaxis.

Main Results:

• MAT vaccines induced strong PBMC proliferation at low concentrations.
• MAT vaccines promoted a Th2/Treg cell shift in cytokine profiles, similar to successful desensitization.
• MAT vaccines demonstrated high efficiency in desensitizing allergic mice and preventing anaphylactic shock.

Conclusions:

• MAT technology enhances antigen presentation via intracellular targeting of the MHC II pathway.
• MAT vaccines are effective in treating allergies by inducing beneficial immune shifts and protection.
• This technology holds potential for both therapeutic allergy treatment and general preventive vaccine development.